Nanjing, China --- Shanghai Intbot Robotics Co., Ltd., a joint venture of Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort^® MedBot^®”) and Biobot Surgical Pte. Ltd. of Singapore, introduced Mona Lisa Robotic Prostate Puncture Positioning System (“Mona Lisa”), completed all the clinical trial operations for robot-assisted prostate puncture biopsy of the center in Nanjing Drum Tower Hospital ， the Affiliated Hospital of Nanjing University Medical School ("Nanjing Drum Tower Hospital") on January 21^st , 2022, symbolizing a staged progress made by the multi-center clinical project of Mona Lisa Robotic Prostate Puncture Positioning System.

 In the previous animal experiments, Mona Lisa has not only displayed the 3D MRI-ultrasound image fusion but also the motion compensation and needle offset position compensation technology has further improved the precision of puncture surgery. Nanjing Drum Tower Hospital, as the primary investigator for Mona Lisa Clinical Trials, completed the enrollment of the first case on the day for the kick-off meeting held on November 22^nd , 2021 as concluding the experience in the previous animal experiments. Led by Professor Hongqian Guo and with the joint efforts of Doctor Shun Zhang, Doctor Haifeng Huang, Doctor Fan Zhang and Doctor Guanchen Zhu, the teamwork advantages were brought into full play, and it took only two months before all clinical enrollment surgery cases had been completed.

 Professor Hongqian Guo said: "Nanjing Drum Tower Hospital has always been the pioneer of robotic surgery, and it is one of the few hospitals in the world that have successfully broken the record of nearly 7,000 robotic surgeries in only six years. Through the close collaboration with MicroPort^® MedBot^®, it is expected that the robot technology will provide the patients with better treatment results, better surgical experience and better quality of life. This clinical research project has fully reflected the superiority of Mona Lisa robotic prostate puncture positioning system’s performance, and we hope that Mona Lisa will be commercialized as soon as possible to benefit more patients.”

 Mr. Yu Liu, Chief Commercial Officer of MicroPort^® MedBot^®, said, "Thanks to Professor Hongqian Guo and his team for their support to Mona Lisa clinical trial project. Nanjing Drum Tower Hospital has always been at the forefront of pioneering clinical diagnosis and treatment technology, serving the vast number of patients with generalized high-end surgical treatment solutions. MicroPort^® MedBot^® will continue to strengthen the collaboration with clinical experts, continue to innovate, accelerate product iteration and domestic substitution, provide the doctors and patients with the robot-assisted intelligent total solutions and ‘Make Surgery Easier, Safer and Less Invasive’”.